IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline

被引:39
|
作者
Scott, George [1 ]
Asrat, Seblewongel [1 ]
Allinne, Jeanne [1 ]
Lim, Wei Keat [1 ]
Nagashima, Kirsten [1 ]
Birchard, Dylan [1 ]
Srivatsan, Subhashini [1 ]
Ajithdoss, Dharani K. [1 ]
Oyejide, Adelekan [1 ]
Ben, Li-Hong [1 ]
Walls, Johnathon [1 ]
Le Floc'h, Audrey [1 ]
Yancopoulos, George D. [1 ]
Murphy, Andrew J. [1 ]
Sleeman, Matthew A. [1 ]
Orengo, Jamie M. [1 ]
机构
[1] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
关键词
IL-4; IL-13; Airway inflammation; Asthma; House dust mite; Lung remodeling; Anti-IL-5; Anti-IL-4R; Type; 2; inflammation; EPITHELIAL BARRIER DYSFUNCTION; RECEPTOR-ALPHA; ANTI-INTERLEUKIN-5; RECEPTOR; DOUBLE-BLIND; TH2; CELLS; ASTHMA; EXPRESSION; MEPOLIZUMAB; BENRALIZUMAB; MULTICENTER;
D O I
10.1016/j.cyto.2022.156091
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Rationale: Type 2 (T2) asthma is characterized by airflow limitations and elevated levels of blood and sputum eosinophils, fractional exhaled nitric oxide, IgE, and periostin. While eosinophils are associated with exacerbations, the contribution of eosinophils to lung inflammation, remodeling and function remains largely hypothetical. Objectives: To determine the effect of T2 cytokines IL-4, IL-13 and IL-5 on eosinophil biology and compare the impact of depleting just eosinophils versus inhibiting all aspects of T2 inflammation on airway inflammation. Methods: Human eosinophils or endothelial cells stimulated with IL-4, IL-13 or IL-5 were assessed for gene changes or chemokine release. Mice exposed to house dust mite extract received anti-IL-4R alpha (dupilumab), antiIL-5 or control antibodies and were assessed for changes in lung histological and inflammatory endpoints. Measurements and main results: IL-4 or IL-13 stimulation of human eosinophils and endothelial cells induced gene expression changes related to granulocyte migration; whereas, IL-5 induced changes reflecting granulocyte differentiation. In a mouse model, blocking IL-4R alpha improved lung function by impacting multiple effectors of inflammation and remodeling, except peripheral eosinophil counts, thereby disconnecting blood eosinophils from airway inflammation, remodeling and function. Blocking IL-5 globally reduced eosinophil counts but did not impact inflammatory or functional measures of lung pathology. Whole lung transcriptome analysis revealed that IL-5 or IL-4R alpha blockade impacted eosinophil associated genes, whereas IL-4R alpha blockade also impacted genes associated with multiple cells, cytokines and chemokines, mucus production, cell:cell adhesion and vascular permeability. Conclusions: Eosinophils are not the sole contributor to asthma pathophysiology or lung function decline and emphasizes the need to block additional mediators to modify lung inflammation and impact lung function.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Suppression of established, ongoing allergic airway inflammation (AAI) by IL-4, IL-13, and IL-4R[alpha] antagonists
    Perkins, Charles
    Orekov, Tatyana
    Khodoun, Marat
    Finkelman, Fred D.
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S289 - S289
  • [22] Oxyresveratrol ameliorates allergic airway inflammation via attenuation of IL-4, IL-5, and IL-13 expression levels
    Ashraf, Muhammad Imran
    Shahzad, Muhammad
    Shabbir, Arham
    CYTOKINE, 2015, 76 (02) : 375 - 381
  • [23] Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling
    Blease, Kate
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (11) : 1180 - 1184
  • [24] Effects Of An Il-4/il-13 Dual Antagonist On Ovalbumin-Induced Lung Inflammation, Airway Hyperresponsiveness, And Ige Production In Mice
    Kasaian, M.
    Marquette, K.
    Fish, S.
    DeClercq, C.
    Agostinelli, R.
    Cook, T. A.
    Brennan, A.
    Lee, J.
    Fitz, L.
    Brooks, J.
    Vugmeyster, Y.
    Williams, C. M. M.
    Lofquist, A.
    Tchistiakova, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [25] Signaling interactions between IL-4 or IL-13 and leukotrienes in allergic inflammation
    Daines, M. O.
    Zornes, P. A.
    Hershey, G. K. Khurana
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S288 - S288
  • [26] Inhibition of IL-4/IL-13 does not enhance the efficacy of allergen immunotherapy in murine allergic airway inflammation
    Gogishvili, Tea
    Hahn, Christian
    Meinhard, Julia
    Hohaus, Andreas
    Erb, Klaus
    Sebald, Walter
    Broecker, Eva B.
    Grunewald, Susanne M.
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2007, 142 (02) : 165 - 174
  • [27] Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation
    Le Floc'h, Audrey
    Allinne, Jeanne
    Nagashima, Kirsten
    Scott, George
    Birchard, Dylan
    Asrat, Seblewongel
    Bai, Yu
    Lim, Wei Keat
    Martin, Joel
    Huang, Tammy
    Potocky, Terra B.
    Kim, Jee H.
    Rafique, Ashique
    Papadopoulos, Nicholas J.
    Stahl, Neil
    Yancopoulos, George D.
    Murphy, Andrew J.
    Sleeman, Matthew A.
    Orengo, Jamie M.
    ALLERGY, 2020, 75 (05) : 1188 - 1204
  • [28] Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation
    Le Floch-ramondou, Audrey
    Nagashima, Kirsten
    Scott, George
    Birchard, Dylan
    Asrat, Seblewongel
    Bai, Yu
    Lim, Wei Keat
    Murphy, Andrew
    Sleeman, Matthew
    Orengo, Jamie
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB158 - AB158
  • [29] Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
    Piazzetta, Giovanna Lucia
    Lobello, Nadia
    Chiarella, Emanuela
    Rizzuti, Alberta
    Pelaia, Corrado
    Pelaia, Girolamo
    Lombardo, Nicola
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (09):
  • [30] IL-13 receptor α 2:: A regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts
    Andrews, Allison-Lynn
    Nasir, Tosia
    Bucchieri, Fabio
    Holloway, John W.
    Holgate, Stephen T.
    Davies, Donna E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (04) : 858 - 865